ARA-290 Protocol: Complete Cycling & Dosing Guide

ARA-290 Protocol: Complete Cycling & Dosing Guide

Overview

ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide that selectively activates the innate repair receptor (IRR) without triggering erythropoietic effects seen with traditional EPO. This distinction makes it a cleaner option for those seeking tissue-protective and anti-inflammatory benefits without red blood cell proliferation or thrombotic risk.

The compound demonstrates measurable efficacy in human trials for neuropathic pain reduction and nerve fiber regeneration, with emerging evidence for broader applications including cardiac health, immune modulation, and tissue repair. However, it remains investigational outside clinical trial settings, and long-term safety data beyond 28 weeks in humans is limited.

Important Context: ARA-290 is not FDA-approved and use outside clinical trials is unregulated. This guide is educational. Consult a qualified healthcare provider before use.

Mechanism of Action & Why Cycling Matters

ARA-290 binds specifically to the innate repair receptor—a heterodimer of the EPO receptor and beta common receptor—which is upregulated in injured and stressed tissues. This activation triggers JAK2/STAT3, PI3K/Akt, and NF-κB pathways, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and promoting cellular survival and neural repair.

Because the IRR is upregulated primarily in damaged tissue, repeated dosing without recovery windows may result in receptor downregulation or diminishing responsiveness. Strategic cycling helps maintain receptor sensitivity and maximizes the therapeutic window with each cycle.

Standard Protocol (General Injury Recovery & Anti-Inflammation)

Dose: 4 mg once daily via subcutaneous injection

Cycle Length: 28 days on, 28-56 days off

Frequency: Every 24 hours (consistent timing)

Administration Route: Subcutaneous injection (abdomen or thigh preferred)

Reconstitution (if lyophilized):

• Reconstitute with bacteriostatic 0.9% sodium chloride or sterile water
• Use 0.5–1 mL per 4 mg vial (concentration: 4–8 mg/mL based on preference)
• Gently swirl—do not shake vigorously
• Let sit 2–3 minutes before drawing
• Store reconstituted solution at 2–8°C (refrigerated)
• Reconstituted peptide is stable for 2–4 weeks if sterile technique is maintained

Storage:

• Lyophilized vials: 2–8°C (refrigerator) or below −20°C (freezer) for extended stability
• Protect from light
• Do not freeze-thaw multiple times once reconstituted

Goal-Specific Protocols

Neuropathic Pain & Small Fiber Neuropathy

Cycle: 28 days on, 42 days off (repeat 3–4 cycles per year)

Dose: 4 mg daily

Rationale: Human RCTs for diabetic neuropathy and sarcoidosis-associated neuropathy used 28-day cycles. Pain reduction and corneal nerve fiber density improvements were observed within 28 days, with effects persisting 28 days post-treatment. Extended off-periods allow receptor re-sensitization before re-introducing the stimulus.

Monitoring: Track neuropathic pain scores (PainDetect questionnaire) at baseline, day 14, day 28, and day 56 (28 days post-cycle). Small fiber density improvements typically require 3–4 consecutive cycles to become clinically meaningful.

Cardiac Health & Aging-Related Inflammation

Cycle: 28 days on, 56 days off (repeat 2–3 times per year)

Dose: 4 mg daily

Rationale: Animal data in aging rats showed significant reductions in cardiac inflammatory markers and improved heart function with chronic dosing. However, to avoid potential adaptation and maintain safety in a long-term wellness context, extended off-periods between cycles are prudent.

Monitoring: Monitor resting heart rate, blood pressure, and subjective energy/exercise tolerance. Improvements in 6-minute walk test distance are a reasonable functional marker.

Acute Injury Recovery (Traumatic or Surgical)

Cycle: 28 days on, starting within 48–72 hours of injury; 56 days off

Dose: 4 mg daily

Rationale: Tissue-protective and anti-inflammatory mechanisms are most effective during the acute inflammatory phase. Starting within the first 72 hours of injury (trauma, surgery) may maximize benefit. One 28-day cycle is typically sufficient; additional cycles may be initiated if recovery is prolonged.

Monitoring: Track wound healing progress, pain levels, inflammatory markers (CRP, if available), and functional capacity (range of motion, strength return, activity tolerance).

Immune Support & Inflammatory Conditions

Cycle: 28 days on, 42 days off (repeat as needed, up to 3–4 cycles per year)

Dose: 4 mg daily

Rationale: Small RCTs in sarcoidosis showed significant symptom improvement within 28 days. Extended rest periods reduce risk of immune system adaptation and allow natural immune tone to re-establish.

Monitoring: Track inflammatory markers (CRP, ESR if available), symptom scores relevant to the condition, and subjective inflammation metrics (joint pain, swelling, fatigue).

How to Administer Step-by-Step

1. Prepare the Injection Site

• Choose abdomen (1–2 inches from navel) or thigh (upper-outer quadrant)
• Alternate sites daily to prevent lipohypertrophy
• Clean with an alcohol wipe; allow 30 seconds to air dry

2. Prepare the Syringe

• Draw room-temperature reconstituted ARA-290 into a 1 mL insulin or tuberculin syringe
• Ensure no air bubbles; tap syringe gently and expel air
• Check that the correct dose (0.5 mL of 8 mg/mL concentration for a 4 mg dose) is drawn

3. Pinch and Inject

• Pinch the skin gently at the injection site
• Insert needle at a 45–90° angle, approximately 1/4 to 1/2 inch deep
• Depress plunger steadily over 3–5 seconds
• Withdraw needle and release skin pinch

4. Post-Injection

• Apply light pressure with alcohol wipe for 30 seconds
• Do not rub; light massage is acceptable
• Dispose of needle in a biohazard sharps container

5. Injection Timing

• Maintain consistent timing (e.g., 8 AM daily)
• Consistency is more important than exact time; ±2 hours is acceptable

Cycle Example: Week-by-Week Schedule (28-Day On Cycle)

| 4 | 4 mg SC daily | Continue through day 28. Consolidate gains. Final assessment at day 28 before entering off-cycle. | | Off-Cycle Days 29–56 (or 29–70) | 0 mg | Allow receptor re-sensitization. Maintain lifestyle factors (sleep, stress, nutrition, movement). Gains typically persist during first 2–3 weeks off-cycle; some regression is normal by week 6–8. |

What to Expect: Timeline of Effects

Days 1–3 (Early Phase)

• Injection site reactions (mild erythema, transient stinging) are common and resolve within hours
• Possible mild nausea or transient lethargy; resolve within 24–48 hours in most users
• No subjective symptomatic improvement yet; anti-inflammatory signaling is initiating at the cellular level

Days 4–7 (Early Response)

• Side effects largely resolve
• Mild energy dip may occur early in week 1; this typically reverses
• No dramatic changes yet, but some users report subtle mood or pain improvements
• Baseline measurements should be finalized by day 7

Days 8–14 (Emerging Window)

• Most measurable improvements begin appearing
• Neuropathic pain reduction becomes noticeable in 40–60% of users
• Fatigue and exercise tolerance may improve
• Inflammatory symptoms (joint pain, swelling, stiffness) often show initial improvements
• Corneal nerve fiber density begins regenerating (measurable by corneal confocal microscopy)

Days 15–28 (Peak Therapeutic Window)

• Maximum anti-inflammatory and tissue-protective effects
• Neuropathic pain improvements are clinically meaningful in responsive individuals
• Improvements in 6-minute walk test and functional capacity
• Corneal nerve fiber density increases become significant
• Energy and mood remain elevated in most users

Days 29–42 (Early Off-Cycle)

• Many gains persist; some regression begins
• Inflammatory markers may gradually begin climbing again
• Neuropathic pain may slowly increase but typically remains below baseline
• Fatigue may gradually re-emerge weeks 5–6

Days 43–56+ (Late Off-Cycle)

• Effects plateau or slowly decay
• Receptor sensitivity re-establishes, preparing for next cycle
• By week 8 of off-cycle, many markers approach baseline
• This is the optimal time to initiate the next cycle if repeating

Common Protocol Mistakes

1. Inconsistent Injection Timing

• Problem: Varying injection times by more than 2–3 hours daily disrupts steady-state plasma levels and receptor occupancy
• Solution: Set a phone alarm and inject at the same time daily (e.g., 8 AM)

2. Premature Cycle Termination

• Problem: Stopping after 10–14 days due to impatience or minor side effects misses the peak therapeutic window (days 15–28)
• Solution: Commit to 28 days regardless of early improvements or mild discomfort. Side effects are typically transient.

3. Skipping Off-Cycles

• Problem: Continuous dosing may lead to receptor downregulation, diminishing returns, and potential immune adaptation
• Solution: Strictly adhere to 28–56 day off-periods between cycles. The off-cycle is when receptor re-sensitization occurs.

4. Incorrect Reconstitution Concentration

• Problem: Over-concentrating peptide (e.g., 4 mg in 0.2 mL) creates hyperosmolar solution, increasing injection site pain and inflammation
• Solution: Reconstitute to 4–8 mg/mL. For daily 4 mg doses, 8 mg/mL allows easy 0.5 mL draws

5. Poor Injection Site Rotation

• Problem: Repeated injections in the same spot cause lipohypertrophy, reduced absorption, and chronic low-grade inflammation
• Solution: Rotate between upper abdomen, lower abdomen, left thigh, and right thigh on a 4-day rotation

6. Ignoring Baseline Measurements

• Problem: Without baseline measurements (pain scores, inflammatory markers, functional tests), it's impossible to objectively assess response
• Solution: Record detailed baselines before cycle day 1: pain (0–10 scale or PainDetect), fatigue (0–10), exercise tolerance (6-minute walk distance if applicable), inflammatory markers (CRP if available)

7. Stacking with Immune-Suppressive Agents Without Caution

• Problem: ARA-290 enhances immune regulation; combining with certain immunosuppressants may potentiate effects unpredictably
• Solution: If using other immune-modulating compounds, consult a provider and allow adequate washout between different immune interventions

How to Stack with Other Compounds

ARA-290 synergizes with compounds that share tissue-protective or anti-inflammatory mechanisms. Timing and spacing matter to avoid receptor saturation.

Stacking with Tissue-Protective Peptides (BPC-157, TB-500)

• Rationale: These peptides share growth factor signaling and anti-inflammatory pathways but activate different receptors
• Protocol: Use BPC-157 or TB-500 on alternate days from ARA-290, or cycle them sequentially (e.g., 28 days ARA-290, 14 days rest, 28 days TB-500, 14 days rest). This prevents receptor saturation and allows each peptide's unique signaling to express.
• Example: Days 1–28 ARA-290 (4 mg daily), days 29–56 off, days 57–84 TB-500 (2.5 mg daily), days 85–112 off. Repeat.

Stacking with Anti-Inflammatory Compounds (Curcumin, Omega-3 Fish Oil, Berberine)

• Rationale: These enhance the anti-inflammatory environment without directly competing for ARA-290 receptors
• Protocol: Use continuously throughout ARA-290 cycles and off-cycles. No timing adjustment needed.
• Example: Curcumin (500 mg 2–3× daily), omega-3 (2–3 g EPA+DHA daily), berberine (500 mg 2–3× daily) throughout all ARA-290 cycles

Stacking with NAD+ Precursors (NMN, NR)

• Rationale: NAD+ enhances mitochondrial function and cellular energy, complementing ARA-290's tissue-protective effects
• Protocol: Use NAD+ precursors continuously or pulse them (e.g., 5 days on, 2 days off). No direct interaction with ARA-290 cycling.
• Example: NMN 500–1000 mg daily, pulsed Monday–Friday, off weekends

Stacking with Collagen Peptides or Amino Acids (for injury recovery)

• Rationale: Collagen peptides provide substrate for tissue repair; amino acids support protein synthesis
• Protocol: Use continuously, especially during ARA-290 on-cycles
• Example: Collagen peptides (10–20 g daily) and beta-alanine (3–5 g daily) throughout

Stacking with Selective Estrogen Receptor Modulators (SARMs) or Anabolic Compounds

• Rationale: ARA-290 offers neuroprotection and anti-inflammatory support; anabolic compounds drive muscle growth
• Protocol: Run ARA-290 cycles and SARM cycles in parallel for synergy, or offset them (ARA-290 during SARM cycle, then both off together)
• Example: ARA-290 (4 mg daily) + LGD-4033 (5 mg daily) for 28 days; 56-day break; repeat
• Caution: Monitor inflammatory markers and liver function with stacked compounds

Stacking with Corticosteroids or Immunosuppressants

• Caution: ARA-290 enhances immune repair and modulation; concurrent use with immunosuppressants may reduce effectiveness of either or create unpredictable immune responses
• Protocol: If necessary, allow 1–2 weeks between cycles. Consult a healthcare provider before combining.

Protocol Quick Reference Table